Stocktoria
Kalaris Therapeutics, Inc. KLRS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-07-30
Chart by TradingView
3/9
Piotroski F — financial health
0.97
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$46.2M | -$51.7M | -$199.9M | -$171.2M | -$169.8M |
| Net income | -$43.4M | -$69.2M | -$190.4M | -$168.7M | -$172.0M |
| Operating cash flow | -$38.4M | -$20.7M | -$124.5M | -$142.1M | -$106.3M |
| Free cash flow | -$38.6M | — | — | — | -$106.3M |
| Total assets | $121.7M | $6.2M | $190.8M | $277.1M | $286.6M |
| Total liabilities | $42.9M | $56.8M | $45.0M | $52.6M | $61.3M |
| Shareholders' equity | $78.8M | -$96.6M | -$45.0M | $224.5M | $225.3M |
| Ratios | |||||
| Return on assets | -35.7% | -1122.5% | -99.8% | -60.9% | -60.0% |
| Return on equity | -55.1% | 71.6% | 423.0% | -75.1% | -76.3% |
| Current ratio | 12.23 | 0.11 | 6.61 | 9.99 | 6.69 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 66,151 | $381,691 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.97 (distress)
- Working capital / assets 0.896
- Retained earnings / assets -1.314
- EBIT / assets -0.379
- Equity / liabilities 1.836
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001754068 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.